EA032385B9 - Pharmaceutical composition for treating gastrointestinal diseases - Google Patents

Pharmaceutical composition for treating gastrointestinal diseases

Info

Publication number
EA032385B9
EA032385B9 EA201791458A EA201791458A EA032385B9 EA 032385 B9 EA032385 B9 EA 032385B9 EA 201791458 A EA201791458 A EA 201791458A EA 201791458 A EA201791458 A EA 201791458A EA 032385 B9 EA032385 B9 EA 032385B9
Authority
EA
Eurasian Patent Office
Prior art keywords
sucralfate
pharmaceutical composition
gastrointestinal diseases
bismuth subcitrate
ranitidine
Prior art date
Application number
EA201791458A
Other languages
Russian (ru)
Other versions
EA201791458A1 (en
EA032385B1 (en
Inventor
Ён Хо Джо
Джун Воо Лее
Original Assignee
Дэвон Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032385(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дэвон Фармасьютикал Ко., Лтд. filed Critical Дэвон Фармасьютикал Ко., Лтд.
Publication of EA201791458A1 publication Critical patent/EA201791458A1/en
Publication of EA032385B1 publication Critical patent/EA032385B1/en
Publication of EA032385B9 publication Critical patent/EA032385B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients and satisfying the following conditions: (a) the sucralfate has an average particle size of 1 to 25 μm, and (b) the bismuth subcitrate has an average particle size of 5 to 90 μm. According to the present invention, when a combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared, it is possible to address a hygroscopicity problem of ranitidine and increase formulation stability and drug bioavailability by controlling particle sizes of sucralfate and bismuth subcitrate.
EA201791458A 2015-01-30 2016-01-28 Pharmaceutical composition for treating gastrointestinal diseases EA032385B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (3)

Publication Number Publication Date
EA201791458A1 EA201791458A1 (en) 2017-11-30
EA032385B1 EA032385B1 (en) 2019-05-31
EA032385B9 true EA032385B9 (en) 2019-07-31

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791458A EA032385B9 (en) 2015-01-30 2016-01-28 Pharmaceutical composition for treating gastrointestinal diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX2017007567A (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
WO2019199134A1 (en) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (en) * 1987-03-09 1992-10-15 Procter & Gamble COMPOSITIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
ES2173183T3 (en) * 1994-04-26 2002-10-16 Chugai Pharmaceutical Co Ltd GRANULATED AND CASTED SUCRALFATE PREPARATION PROCEDURE.
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio equipment
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
AU8354498A (en) * 1997-08-25 1999-03-16 Procter & Gamble Company, The Combined preparations for treating upper gastrointestinal tract distress
CN1173698C (en) 1999-06-21 2004-11-03 株式会社大熊制药 Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
KR101617054B1 (en) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical composition for preventing or treating a gastroenteric disease comprising ilaprazole and a mixture of sucralfate and bismuth agents
KR20140072673A (en) 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
TWI635859B (en) 2018-09-21
ECSP17038599A (en) 2017-09-29
KR20160094268A (en) 2016-08-09
EP3250199A2 (en) 2017-12-06
MY195824A (en) 2023-02-22
SA517382016B1 (en) 2021-03-18
AR105413A1 (en) 2017-10-04
CN107205947B (en) 2020-05-22
KR101583452B1 (en) 2016-01-11
EP3250199A4 (en) 2018-08-08
WO2016122226A2 (en) 2016-08-04
JP2018503672A (en) 2018-02-08
MX2017007567A (en) 2017-10-19
CN107205947A (en) 2017-09-26
TW201639559A (en) 2016-11-16
UA116517C2 (en) 2018-03-26
PH12017550051A1 (en) 2018-01-29
CL2017001680A1 (en) 2018-01-12
PE20171340A1 (en) 2017-09-13
CO2017006222A2 (en) 2017-09-20
EA201791458A1 (en) 2017-11-30
EA032385B1 (en) 2019-05-31
JP6419347B2 (en) 2018-11-07
KR101583452B9 (en) 2022-05-02
WO2016122226A3 (en) 2016-09-15
GEP20196941B (en) 2019-01-10
BR112017013857A2 (en) 2018-02-27
MA41432A (en) 2017-12-05

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
JP2015078230A5 (en)
EP3895717A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
PH12020550341A1 (en) Niraparib formulations
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
CN108026053A8 (en) Condensed glyoxaline compound as mIDH1 inhibitor
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
WO2016142708A3 (en) Pharmaceutical composition
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
EP3417853A4 (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
JO3256B1 (en) Formulations of Organic Compounds
MX2023006235A (en) Compositions for drug delivery and methods of use thereof.
EA032385B9 (en) Pharmaceutical composition for treating gastrointestinal diseases
WO2015001541A3 (en) Pharmaceutical film composition
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
EA202091561A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT
PH12019500024A1 (en) Pharmaceutical compositions
EP3360581A4 (en) Pharmaceutical composition for preventing or treating cancer comprising inhibitor of plrg1 (pleiotropic regulator 1) as active ingredient
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM